2014
Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics
Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinChemoradiotherapy, AdjuvantDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansHysterectomyLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelRetrospective StudiesSurvival RateTreatment FailureConceptsDisease-free survivalVaginal cuff brachytherapyStage III endometrial adenocarcinomaStage III endometrial cancerNode-negative diseaseOverall survivalAdjuvant chemotherapyEndometrial cancerEndometrial adenocarcinomaType IComprehensive surgical stagingLow-risk histologyNode-positive diseaseOutcomes of patientsHigh-risk histologyNode-positive ratePatterns of recurrenceAnalysis of outcomesType II diseaseAdjuvant carboplatinVaginal failuresSurgical stagingAdjuvant therapyNode negativeNode positivePhase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.Peer-Reviewed Original ResearchConceptsOral topotecanEndometrial cancerDay 1Pelvic external beam radiation therapyMammalian targetExternal beam radiation therapyPhase I clinical trialRecurrent endometrial cancerAdvanced endometrial cancerDose-limiting toxicityEfficacy of topotecanRapamycin inhibitor everolimusBeam radiation therapyOral everolimusStable diseaseVaginal brachytherapyMedian ageRapamycin inhibitorsInhibitor everolimusPreclinical dataClinical trialsMedian numberPharmacokinetic assessmentRadiation therapyEverolimusBasal Subtype, as Approximated by Triple-Negative Phenotype, is Associated with Locoregional Recurrence in a Case–Control Study of Women with 0–3 Positive Lymph Nodes After Mastectomy
Khan AJ, Milgrom SA, Barnard N, Higgins SA, Moran M, Shahzad H, Kim S, Goyal S, Al-Faraj F, Kirstein L, Kearney T, Haffty BG. Basal Subtype, as Approximated by Triple-Negative Phenotype, is Associated with Locoregional Recurrence in a Case–Control Study of Women with 0–3 Positive Lymph Nodes After Mastectomy. Annals Of Surgical Oncology 2014, 21: 1963-1968. PMID: 24562930, PMCID: PMC5723128, DOI: 10.1245/s10434-014-3512-1.Peer-Reviewed Original ResearchConceptsPositive lymph nodesPostmastectomy RTTriple-negative phenotypeLymph nodesBasal subtypeHigher LRROdds ratioResultsOn univariate analysisEvidence of diseaseUse of chemotherapyCase-control studyCohort of womenConditional logistic regressionParaffin-embedded tissue blocksLocoregional recurrencePositive nodesBiologic subtypeUnivariate analysisTN phenotypeER-PRConclusionsOur dataMastectomy specimenTissue microarrayLower oddsMastectomy
2013
Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes?
Bai HX, Motwani SB, Higgins SA, Haffty BG, Wilson LD, Lannin DR, Evans SB, Moran MS. Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes? International Journal Of Clinical Oncology 2013, 19: 460-466. PMID: 23780727, DOI: 10.1007/s10147-013-0575-0.Peer-Reviewed Original ResearchConceptsBreast conservation treatmentLocal relapse-free survivalRelapse-free survivalSigns/symptomsLong-term outcomesDCIS patientsPhysical signs/symptomsTumor sizeER/PR/HERWorse long-term prognosisSignificant overall survival differenceAdjuvant hormone treatmentLong-term prognosisOverall survival differenceBreast conservation therapyLarger tumor sizeStatus of marginsNon-white racePresentation of diseaseMedian followClinicopathological differencesNodal involvementOverall survivalIndependent predictorsConservation therapy